Trials / Completed
CompletedNCT02276053
Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
A Noninterventional Study of Vimpat® (Lacosamide) as Adjunctive Antiepileptic Drug Therapy in Patients With Brain Tumor-related Epilepsy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 93 (actual)
- Sponsor
- UCB BIOSCIENCES GmbH · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to find out whether lacosamide (a drug to treat epilepsy) is effective in routine clinical practice for patients with epilepsy caused by a brain tumor.
Conditions
Timeline
- Start date
- 2014-11-27
- Primary completion
- 2017-12-04
- Completion
- 2017-12-04
- First posted
- 2014-10-27
- Last updated
- 2020-06-01
- Results posted
- 2019-08-19
Locations
24 sites across 6 countries: France, Germany, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02276053. Inclusion in this directory is not an endorsement.